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Hyperthermic Perfusion 16 Years After its First Clinical Applications
R. Cavaliere,* G . Moricca,* F. Di Filippo,* L. Aloe,* G. Monticelli,** and F. S. Sartori**

It is known that above-normal temperatures (42°-42.5°C)
provoke selective damage to neoplastic cells. We used
heated circulating blood as a method for heat transfer on
patients with limb tumors. From October 1964 to December 1979, we treated a total of 198 patients with hyperthermic perfusion
for melanoma
of the limbs
(91),
osteosarcoma (57), and soft tissue sarcoma (50). For
melanoma patients, the five-year survival rate, excluding
Stage IV, was 60%. For patients with soft tissue sarcoma,
the five-year survival rates were 53% and 56% for hyperthermic perfusion and hyperthermic antiblastic perfusion.

respectively. For 29 patients with osteosarcoma, hyperthermic perfusion was combined with systematic amputation
ofthe limb for a 60% survival rate over a five-year period.
Newer studies with osteosarcoma patients involve a multistep treatment that saves the tumor-bearing limb without
reducing survival rates. Our 16-year clinical trial demonstrates that hyperthermia is effective in curing some tumors
of the limbs, especially osteosarcoma and melanoma. We
believe that perfusion remains the most reliable heat transfer method for loco-regional treatment and perhaps even
for whole-body treatment for limb tumors.

It is known that above-normal temperatures (42°-42.5°C)
provoke selective damage to neoplastic cells (1-9). Many
published reports on the treatment of tumors by hyperthermia have demonstrated that, however the treatment is
applied, hyperthermia is capable of producing positive
results that, in some tumors, could not be obtained with
conventional treatments.

Forthe upper limbs, the axillary artery and vein are cannulated and connected to a heart-lung machine, previously
primed with an isotonic solution. An electromagnetic
flowmeter and polygraph are inserted into the arterial line
to record perfusion flows and pressures. A thermistor is
inserted just next to the arterial cannula to monitor the
actual temperature of the blood entering the artery. No
tourniquet is used at the root o f t h e limb when hyperthermic perfusion is performed. Needle probes of the thermocouples are inserted into the muscles of the arm and
forearm and into different parts ofthe tumor; other probes
are inserted into the rectum and mid-thoracic esophagus.
All thermometers are connected to a computerized control
system.

As previously published (10-12), we used heated circulating
blood to apply as a method for heat transfer on humans.
Sixteen years after the first clinical applications, we consider the results that we obtained with hyperthermic perfusion to be satisfactory for treating limb tumors. In some
tumors, however, hyperthermic perfusion did not bring
about complete c o n t r o l of the disease; thus, various
therapy protocols presently employ a multi-step treatment
to optimize the selective effect of the heat.

When perfusion begins, the temperature ofthe arterial line
is 38°C and is gradually raised to 42.5°C and even to 43°C
in the heat exchanger. Perfusional pressure, kept slightly
higherthan the systemic pressure, is constantly regulated
accordingto the modifications in the central venous pressure. Flows are predetermined but subjectto adjustments
depending on the amount of return venous flow.

Materials and Methods
Our technique for performing hyperthermic perfusion,
which was standardized afterthe first series of trials, can be
summarized as follows:

After 45-60 minutes of perfusion, when the temperature of
the tumor reaches 42°C, the hyperthermic treatment begins. Perfusion takes from two to four hours, depending on
the size and the histological type of tumor, and, of course,
on the condition o f t h e patient. Afterwards, the circuit is
washed out wfth an isotonic solution containing 1 million
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I.U. of anti-callycrein, and the vessel incisions are sutured.
During hyperthermic treatment and for a few days thereafter, controlled osmotic diuresis and low-level metabolic
alcalosis are maintained. The lost blood is reintegrated.

great differences between the results obtained with hyperthermic perfusion and those obtained wfth hyperthermic
antiblastic perfusion. As has been reported previously (12,
15), in cases of loco-regional spreading melanoma, hyperthermic perfusion without the use of antiblastic drugs
appears to be more effective. However, these results will
soon be more accurately confirmed by a randomized study
presently underway.

Forthe lower limbs, the surgical approach involves the iliac
or femoral vessels. The procedure for hyperthermic perfusion is the same.
For many years now we have been performing a sympathectomy at the time of perfusion. We use the same
surgical approach to prepare and expose the vessels o f t h e
limb to be perfused. For the upper limbs, this involves
removing part ofthe sympathetic chain between the proximal part of the stellate ganglion and the third dorsal
ganglion. The proximal part ofthe stellate ganglion is left in
situ to avoid causing the Bernard-Horner syndrome. For
lower limb tumors, the sympathectomy involves removing
the last three lumbar ganglions.

Hyperthermic perfusion, as we have stated, can also be
combined with the administration of antiblastic drugs. For
the treatment of melanoma, 1-1.2 mg/kg of body weight of
melphalan is used, and for osteosarcoma and soft tissue
sarcoma, 0.8 mg/kg, followed by 0.015 mg/kg of actinomycin-D. The duration o f t h e hyperthermic antiblastic
treatment never exceeds 120 minutes.
Osteosarcoma
Between October 1964 and December 1979, 57 patients
with osteosarcoma underwent hyperthermic treatment.
The first nine were subjected to hyperthermic perfusion
without further treatment, and three of them today are free
of disease, 8, 10, and 11 years after treatment. In the other
six cases, the patients died of metastases.

Results
From October 1964 to December 1979, we treated a total
of 198 patients w i t h hyperthermic perfusion for l i m b
tumors.

To improve our results, we combined hyperthermic perfusion and/or hyperthermic antiblastic perfusion with systematic amputation ofthe limb a few weeks after perfusion.
The time lapse between perfusion and amputation was
arbitrarily set at four weeks, based on previous results
which suggested that the presence of perfused tumor cells
helped significantly in preventing further metastases.

Melanoma of the limbs
We treated 91 patients with limb melanoma either by
hyperthermic perfusion or hyperthermic antiblastic perfusion (Table I). We have adopted the tumor classification
system of the M.D. Anderson Hospital and Tumor Institute
(Houston, Texas). Today, perfusion is being performed to
treat Stage I melanoma, if Clark's histological level is 111 or
more (13), and/or if the tumor is at least 1.5 mm thick,
according to Breslow (14). A lymphadenectomy is performed only when the lymph nodes are involved.

We treated 29 patients according to this procedure with a
60% rate of success over a five-year period, according to
the Kaplan-Meier actuarial method (16), 12 with hyperthermic perfusion and 17 with hyperthermic antiblastic perfusion. This rate is far better than those obtained w i t h
conventional treatment, where major radical surgery is
performed (12). Furthermore, analyses of tumors that were
excised during amputation showed that hyperthermic perfusion had caused extensive necrosis and that the tumors
were surrounded by a zone of bone sclerosis fthe stop
effect), similiar in appearance to the sclerotic borderline of
a benign tumor (Fig. 1).

O u r five-year survival rate for patients treated for
melanoma, excluding Stage iV, was 60%. There are no

TABLE I
Melanoma of the Limbs
Hyperthermic Perfusion
*Stages
Patients (30)
1
II
IIIA
IIIB

3
3
6
6

IIIAB
IV

6
6

Hyperthermic Antiblastic Perfusion
Patients (61)

In 1975, we began new studies to see whether or not it was
possible to save the tumor-bearing limb without reducing
the survival rates. This involves a mufti-step treatment,
including hyperthermic antiblastic perfusion, en-bloc resection when possible, bone reconstruction (with metallic
endoprostheses or autoplastic bone grafts), and adjuvant
chemotherapy. O f t h e nine patients who were treated with
this procedure, five are alive and free of disease, with the
limb intact, 19-51 months after treatment.

7
10
14
9
12
9

* According to the tumor classification system of the M.D. Anderson
Hospital and Tumor Institute (Houston, Texas)
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Fig. 1
Osteogenic sarcoma of distal part of radius.
Left: Before perfusion; right: Clinical results two years later, with complete bone repair.

Soft tissue sarcoma

in advanced stages (II, III, IVA, according to the American
Joint Committee classification).

Between October 1964 and December 1979, we treated 50
patients with soft tissue sarcoma either by hyperthermic
perfusion or hyperthermic antiblastic perfusion, followed
by excision ofthe tumor or amputation, depending on the
histological type of the cancer, its size, and site. The fiveyear survival rates were 53% and 56% for hyperthermic
perfusion and hyperthermic antiblastic perfusion, respectively. Therefore, no significant differences exist between
the two techniques.

Our objectives were two-fold: 1) loco-regional control of
the tumor without the need for radical surgery; 2) distant
control of the disease through the enhancement of the
immune system and adjuvant chemotherapy. Our preliminary results have confirmed that this multi-step treatment
can achieve loco-regional control o f t h e disease. In terms
of regained functionality, the results are very satisfactory,
better than those obtained with conservative surgery. Of ten
patients treated, only two died (12 and 19 months after
treatment) due to lung metastasis. To confirm these preliminary results, this procedure will have to be performed
on a greater number of patients. We have also had positive
results with hyperthermic perfusion alone, in cases of
primary soft tissue sarcoma, when the tumor is not excessively large (Figs. 2-4).

However, even i f w e consider that all the patients with soft
tissue sarcoma had previously been treated with radiochemotherapy, we cannot be entirely satisfied with our
results. Recurrences have appeared, so that hyperthermic
perfusion alone does not completely achieve loco-regional
control of the tumor.
With these considerations in mind, we have begun a new
treatment protocol in which hyperthermic perfusion, as a
first step, is followed, at random, either by an endo-arterial
infusion (adriamycin) or radiotherapy. After the tumor has
been excised, adjuvant chemotherapy is administered only

Discussion
Today, 16 years after our first clinical experiences treating
cancer of the extremities by hyperthermic perfusion, some
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Fig. 2
Large recurrent fibrosarcoma of the thigh before hyperthermic
pertusion.

Fig. 4
Clinical results, one year later, with a complete range of movements.

definitive observations can be made. Clinically, we have
demonstrated that hyperthermia is effective in curing some
tumors o f t h e limbs, even in cases in which poor results
were obtained with conventional treatments. Many techniques have been developed to obtain above-normal temperatures in a particular part of the body as well as in the
entire body, but in light of our results, we believe that
perfusion still remains the most reliable heat transfer
method, certainly for loco-regional treatment and perhaps
even for whole-body hyperthermia. Hyperthermic perfusion permits us to control and maintain above-normal
temperatures over the entire tumor site uniformly and
constantly.
Although the first clinical applications of this technique
presented complications, once we became more familiar
with the physiopathology of hyperthermia, complications
were reduced to a minimum. The operative mortality rate
has been reduced to approximately 3%, which is considered normal in a routine operation.

Fig. 3
Radical conservative excision of the tumor mass, sparing the sciatic
nerve and femoral vessels.
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Another difficulty we encountered was what we have
called "post-perfusional limb syndrome." During followup, patients complained of persistent, diffused, and often
burning pain, probably brought about by the autonomic
nervous system. Since this could represent a form of reflexsympathetic dystrophy, we performed a sympathectomy at
the same time as the perfusion, which did not greatly
complicate the surgical operation in terms of exposing and
preparing the vessels of the limb. As a result, the pain
described was no longer observed. The association o f t h e
sympathectomy with perfusion considerably reduced
edema and postperfusional venous stasis.

We still do not know whether or not the mortality rate
should be attributed to an incomplete capacity of the
enhanced immune response that perfusion appears to
evoke in the host, as far as pre-existing micrometastasis is
concerned. This appears to be the most suitable explanation because we have neither recurrences nor metastases in
the perfused area.

Conclusions
Our d i n ical experience has proved that hyperthermic perfusion can be considered completely effective in curing
some limb tumors. Theoretically, whole body hyperthermia, exposing all the neoplastic populations to abovenormal temperatures, would be the most complete treatment of tumors. We believe that circulating blood remains
the best method for heat transfer and could also be employed for a whole-body treatment. We have employed a
whole-body treatment on only a very limited number of
patients, using an aortal-caval shunt; these first applications indicate that with the proper improvements, it could
become an effective treatment for tumors.

The survival rates of patients with limb tumors, principally
w i t h advanced osteosarcoma and m e l a n o m a , are extremely satisfying. Complete loco-regional control has
been obtained, a result of remarkable value, particularly in
osteosarcoma, because it permits us to save the limb. In
fact, we have begun a protocol treatment which involves,
whenever possible, the en-bloc resection of the tumor in
orderto preserve the tumor-bearing limb. These considerations take on an even greater importance in that osteosarcoma mainly affects patients in their second decade of life.
Of the nine patients treated, five are alive with no sign of
disease, for a period ranging between 19 and 51 months.

References
1. Mondovi B, Strom R, Rotilio G, Finazzi Agro A, Cavaliere R, RossiFanelli A. The biochemical mechanism of selective heat sensitivity of
cancer cells. I. Studies on cellular respiration. Europ J Cancer 1969;
5:129-36.

9. Strom R, Crifo C, Bozzi A, Rossi-Fanelli A. Inhibition by elevated
temperature of ribosomal RNA maturation in Ehrlich ascite cells.
Cancer Biochem Biophys 1975;1:57.
10. B o u r d o n G, H a l p e r n M B . I m m u n i t e a n t i t u m o r a l e i n d u i t e par
I'administration de cellules tumorales homologues at isologues
traitees par chauffage menage. CR Acad Sci Paris 1976;282(D):
1571-74.

2. Mondovi B, Finazzi Agro A, Rotilio G, Strom R, Moricca G, RossiFanelli A. The biochemical mechanism of selective heat sensitivity of
cancer cells. II. Studies on nucleic acids and protein synthesis. Europ J
Cancer 1969;5:137-46.

11. Cavaliere R. Regional hyperthermia by perfusion. In: Proc, International Symposium on Cancer Therapy by Hyperthermia and Radiation. Baltimore: Am College Radiology Press, 1976.

3. Mondovi B. Biochemical and ultrastructural lesions. Proc, Int Symposium on Cancer Therapy by Hyperthermia and Radiation, Washington, DC, April 28-30, 1975.
4. Mondovi B, Strom R, Finazzi Agro A, et al. Effect of polyenic
antibiotics on Ehrlich ascites and Novikoff hepatoma cells. Cancer
Res 1971;31:505-09.

12. Moricca G, Cavaliere R, Caputo A, Biogotti A, Clistro F Hyperthermic
treatment of tumors: Experimental and clinical applications. In: Recent results in cancer research. Berlin, Heidelberg, New York:
Springer Verlag, 1977:112-51.

5. Giovanella BC, Mosti R, Heidelberger C. Biochemical and biological
effects of heaton normal and neoplastic cells. Proc Ann Assoc Cancer
Res 1969:10:28.

13. Clark W H Jr, Fromm EAL, Bernardino EA, Mihm MC.The histogenesis
and biological behaviours of primary human mal ignant melanomas of
the skin. Cancer Res 1969;29:705-26.

6. Giovanella BC, Morgan CA, Stehlin JS, Williams LJ. Selective lethal
effect of supranormal temperature on mouse sarcoma cells. Cancer
Res 1973;33:2568-78.

14. Breslow A. Thickness, cross-sectional areas and depth of invasion in
the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-08.
15. Cavaliere R, Moricca G, Di Filioppo F, Caputo A, Santori FS, M o n ticelli G. Heat transfer problems during local perfusion in cancer
treatment. Ann NY Acad Sci 1980;335:311.

7. Giovanella BC, Mondovi B. Selective heat sensitivity of cancer cells.
In: Rossi-Fanelli A, Cavaliere R, Mondovi B, Moricca G, eds. Recent
results in cancer research. Berlin, Heidelberg, New York: Springer
Verlag, 1977:1-6.

16. Kaplan ELM. Non parametric estimation from incomplete observation.
Am Stat Oss J June 1938.

8. Strom R, Scioscia Santoro A, Crifo C, Bozzi A, Mondovi B, RossiFanelli A. The biochemical mechanism of selective heat sensitivity of
cancer cells. IV. Inhibition of RNA synthesis. Europ J Cancer 1973;
9:103-12.

36

